Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around ...

Vertex Pharmaceuticals is backed by CF dominance and JOURNAVX optionality, with key catalysts ahead for growth and upside.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $388.55, marking a -2% move from the previous day. This change lagged the S&P 500's 0.3% gain on the day. Elsewhere, the Dow saw ...

Vertex is defying the bear market, up 30% so far this year. The company is a leader in the cystic fibrosis market and generates billions of dollars annually from its treatments for that condition.

Vertex Pharmaceuticals (VRTX) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceuticals has a ...

Vertex's P/S ratio is very high, relative to most other biopharma stocks. It's important, though, to look to the future rather than the past when considering the company's valuation. Vertex could even ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference ...

- Ono will leverage its deep expertise in clinical development and commercialization for chronic kidney disease in Japan and South Korea to accelerate advancement of povetacicept for patients with IgA ...